dalteparin has been researched along with Death, Sudden, Cardiac in 6 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Death, Sudden, Cardiac: Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A recent randomized, controlled trial, the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS 5) trial, reported that major bleeding was 2-fold less frequent with fondaparinux than with enoxaparin in acute coronary syndromes (ACS)." | 9.12 | Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Fox, KA; Mehta, SR; Moccetti, T; Piegas, LS; Theroux, P; Valentin, V; Wallentin, L; Yusuf, S, 2007) |
| "A recent randomized, controlled trial, the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS 5) trial, reported that major bleeding was 2-fold less frequent with fondaparinux than with enoxaparin in acute coronary syndromes (ACS)." | 5.12 | Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Fox, KA; Mehta, SR; Moccetti, T; Piegas, LS; Theroux, P; Valentin, V; Wallentin, L; Yusuf, S, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| White, HD | 1 |
| Braunwald, E | 2 |
| Murphy, SA | 1 |
| Jacob, AJ | 1 |
| Gotcheva, N | 1 |
| Polonetsky, L | 1 |
| Antman, EM | 2 |
| Scirica, BM | 1 |
| Morrow, DA | 1 |
| Sadowski, Z | 1 |
| Ruda, M | 1 |
| Nicolau, JC | 1 |
| Giugliano, RP | 1 |
| Wiviott, SD | 1 |
| Sabatine, MS | 1 |
| Shui, A | 1 |
| Fox, KA | 2 |
| Bassand, JP | 1 |
| Mehta, SR | 1 |
| Wallentin, L | 1 |
| Theroux, P | 1 |
| Piegas, LS | 1 |
| Valentin, V | 1 |
| Moccetti, T | 1 |
| Chrolavicius, S | 1 |
| Afzal, R | 1 |
| Yusuf, S | 1 |
| Hilpert, U | 1 |
| Arnheim, K | 1 |
2 reviews available for dalteparin and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials.
Topics: Angina, Unstable; Anticoagulants; Clinical Trials as Topic; Dalteparin; Death, Sudden, Cardiac; Enox | 1999 |
[Long-term administration of Dalteparin in unstable coronary syndrome. FRISC II study opens novel therapeutic perspectives. Fragmin and Fast Revascularization during Instability in Coronary Artery Disease].
Topics: Angina, Unstable; Anticoagulants; Controlled Clinical Trials as Topic; Dalteparin; Death, Sudden, Ca | 2000 |
3 trials available for dalteparin and Death, Sudden, Cardiac
1 other study available for dalteparin and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Care for life. Central is the patient.
Topics: Angina, Unstable; Anticoagulants; Awards and Prizes; Death, Sudden, Cardiac; Enoxaparin; Germany; Hu | 2000 |